1. Home
  2. DYN vs LGIH Comparison

DYN vs LGIH Comparison

Compare DYN & LGIH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DYN
  • LGIH
  • Stock Information
  • Founded
  • DYN 1984
  • LGIH 2003
  • Country
  • DYN United States
  • LGIH United States
  • Employees
  • DYN N/A
  • LGIH N/A
  • Industry
  • DYN Medicinal Chemicals and Botanical Products
  • LGIH Homebuilding
  • Sector
  • DYN Health Care
  • LGIH Consumer Discretionary
  • Exchange
  • DYN Nasdaq
  • LGIH Nasdaq
  • Market Cap
  • DYN 2.6B
  • LGIH 2.3B
  • IPO Year
  • DYN 2020
  • LGIH 2013
  • Fundamental
  • Price
  • DYN $25.95
  • LGIH $96.88
  • Analyst Decision
  • DYN Strong Buy
  • LGIH Hold
  • Analyst Count
  • DYN 11
  • LGIH 5
  • Target Price
  • DYN $51.18
  • LGIH $122.40
  • AVG Volume (30 Days)
  • DYN 836.3K
  • LGIH 174.3K
  • Earning Date
  • DYN 11-12-2024
  • LGIH 11-05-2024
  • Dividend Yield
  • DYN N/A
  • LGIH N/A
  • EPS Growth
  • DYN N/A
  • LGIH 9.16
  • EPS
  • DYN N/A
  • LGIH 8.36
  • Revenue
  • DYN N/A
  • LGIH $2,253,616,000.00
  • Revenue This Year
  • DYN N/A
  • LGIH N/A
  • Revenue Next Year
  • DYN N/A
  • LGIH $22.02
  • P/E Ratio
  • DYN N/A
  • LGIH $11.70
  • Revenue Growth
  • DYN N/A
  • LGIH 0.68
  • 52 Week Low
  • DYN $11.66
  • LGIH $84.00
  • 52 Week High
  • DYN $47.45
  • LGIH $136.89
  • Technical
  • Relative Strength Index (RSI)
  • DYN 38.55
  • LGIH 33.09
  • Support Level
  • DYN $25.27
  • LGIH $98.00
  • Resistance Level
  • DYN $28.96
  • LGIH $101.52
  • Average True Range (ATR)
  • DYN 1.41
  • LGIH 3.18
  • MACD
  • DYN -0.23
  • LGIH -1.20
  • Stochastic Oscillator
  • DYN 14.25
  • LGIH 1.29

About DYN Dyne Therapeutics Inc.

Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.

About LGIH LGI Homes Inc.

LGI Homes Inc is engaged in the design, construction, and sale of new homes in markets. The company current product offerings include entry-level homes, including both detached homes and townhomes, and move-up homes sold, which are sold under LGI Homes brand, and luxury series homes, which are sold under the Terrata Homes brand. It offers a set number of floor plans in each community with features that include upgrades, such as granite countertops, appliances, and ceramic tile flooring. They have seven operating segments ( Central, Midwest, Southeast, Mid-Atlantic, Northwest, West and Florida divisions) that it aggregates into five qualifying reportable segment. Majority of the revenue is generated from Central division segment.

Share on Social Networks: